|
1
|
Chen Y and Hu L: Design of anticancer
prodrugs for reductive activation. Med Res Rev. 29:29–64. 2009.
View Article : Google Scholar
|
|
2
|
Chen Z, Zhang D, Yue F, Zheng M, Kovacevic
Z and Richardson DR: The iron chelators Dp44mT and DFO inhibit
TGF-β-induced epithelial-mesenchymal transition via up-regulation
of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem.
287:17016–17028. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupte A and Mumper RJ: Elevated copper and
oxidative stress in cancer cells as a target for cancer treatment.
Cancer Treat Rev. 35:32–46. 2009. View Article : Google Scholar
|
|
4
|
Pahl PM and Horwitz LD: Cell permeable
iron chelators as potential cancer chemotherapeutic agents. Cancer
Invest. 23:683–691. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kalinowski DS, Sharpe PC, Bernhardt PV and
Richardson DR: Structure-activity relationships of novel iron
chelators for the treatment of iron overload disease: The methyl
pyrazinylketone isonicotinoyl hydrazone series. J Med Chem.
51:331–344. 2008. View Article : Google Scholar
|
|
6
|
Chaston TB, Watts RN, Yuan J and
Richardson DR: Potent antitumor activity of novel iron chelators
derived from di-2-pyridylketone isonicotinoyl hydrazone involves
Fenton-derived free radical generation. Clin Cancer Res.
10:7365–7374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filipović N, Borrmann H, Todorović T,
Borna M, Spasojević V, Sladić D, Novaković I and Anđelković K:
Copper(II) complexes of N-heteroaromatic hydrazones: Synthesis,
X-ray structure, magnetic behavior, and antibacterial activity.
Inorg Chim Acta. 362:1996–2000. 2009. View Article : Google Scholar
|
|
8
|
Hoyes KP, Hider RC and Porter JB: Cell
cycle synchronization and growth inhibition by
3-hydroxypyridin-4-one iron chelators in leukemia cell lines.
Cancer Res. 52:4591–4599. 1992.PubMed/NCBI
|
|
9
|
Chaston TB and Richardson DR: Interactions
of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of
chelators with iron and DNA: Implications for toxicity in the
treatment of iron overload disease. J Biol Inorg Chem. 8:427–438.
2003.PubMed/NCBI
|
|
10
|
Chaston TB, Lovejoy DB, Watts RN and
Richardson DR: Examination of the antiproliferative activity of
iron chelators: Multiple cellular targets and the different
mechanism of action of triapine compared with desferrioxamine and
the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin
Cancer Res. 9:402–414. 2003.PubMed/NCBI
|
|
11
|
Turner J, Koumenis C, Kute TE, Planalp RP,
Brechbiel MW, Beardsley D, Cody B, Brown KD, Torti FM and Torti SV:
Tachpyridine, a metal chelator, induces G2 cell-cycle
arrest, activates checkpoint kinases, and sensitizes cells to
ionizing radiation. Blood. 106:3191–3199. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu Y, Zhou S, Liu Y, Yang Y, Sun X and Li
C: The cytotoxicity of benzaldehyde nitrogen mustard-2-pyridine
carboxylic acid hydrazone being involved in topoisomerase IIα
inhibition. BioMed Res Int. 2014:5270422014. View Article : Google Scholar
|
|
13
|
Zheng X, Zhao Y and Zhu BX: Coordination
of the new Schiff base with copper(II) or Iron(III) in solution.
Wuji Huaxue Xuebao. 27:1523–1528. 2011.In Chinese.
|
|
14
|
Singh NP, McCoy MT, Tice RR and Schneider
EL: A simple technique for quantitation of low levels of DNA damage
in individual cells. Exp Cell Res. 175:184–191. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu Y, Zhang Y, Zhou SF, Liu Y, Wang J,
Wang Y, Lu C and Li C: The effects of substitution of carboxyl with
hydrazide group on position 3 of ciprofloxacin on its antimicrobial
and antitumor activity. Int J Pharm. 9:416–429. 2013. View Article : Google Scholar
|
|
16
|
Banerjee S, Sen S, Basak S, Mitra S,
Hughes DL and Desplanches C: Two new pseudohalide-bridged Cu(II)
complexes with a hydrazone ligand: Syntheses, crystal structures
and magnetic studies. Inorg Chim Acta. 361:2707–2714. 2008.
View Article : Google Scholar
|
|
17
|
Buss JL, Neuzil J and Ponka P: Oxidative
stress mediates toxicity of pyridoxal isonicotinoyl hydrazone
analogs. Arch Biochem Biophys. 421:1–9. 2004. View Article : Google Scholar
|
|
18
|
Jansson PJ, Hawkins CL, Lovejoy DB and
Richardson DR: The iron complex of Dp44mT is redox-active and
induces hydroxyl radical formation: An EPR study. J Inorg Biochem.
104:1224–1228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Becker E and Richardson DR: Development of
novel aroylhydrazone ligands for iron chelation therapy:
2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin
Med. 134:510–521. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gillardon F, Wickert H and Zimmermann M:
Up-regulation of bax and down-regulation of bcl-2 is associated
with kainate-induced apoptosis in mouse brain. Neurosci Lett.
192:85–88. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Niu G, Yin S, Xie S, Li Y, Nie D, Ma L,
Wang X and Wu Y: Quercetin induces apoptosis by activating
caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in
human HL-60 cells. Acta Biochim Biophys Sin. 43:30–37. 2011.
View Article : Google Scholar
|
|
22
|
Turski ML and Thiele DJ: New roles for
copper metabolism in cell proliferation, signaling, and disease. J
Biol Chem. 284:717–721. 2009. View Article : Google Scholar :
|
|
23
|
Jain S, Cohen J, Ward MM, Kornhauser N,
Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, et al:
Tetrathiomolybdate-associated copper depletion decreases
circulating endothelial progenitor cells in women with breast
cancer at high risk of relapse. Ann Oncol. 24:1491–1498. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tardito S and Marchiò L: Copper compounds
in anticancer strategies. Curr Med Chem. 16:1325–1348. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skrott Z and Cvek B:
Diethyldithiocarbamate complex with copper: The mechanism of action
in cancer cells. Mini Rev Med Chem. 12:1184–1192. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou BB and Elledge SJ: The DNA damage
response: Putting checkpoints in perspective. Nature. 408:433–439.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmad M, Afzal M, Tabassum S, Kalińska B,
Mrozinski J and Bharadwaj PK: Synthesis and structure elucidation
of a cobalt(II) complex as topoisomerase I inhibitor: In vitro DNA
binding, nuclease and RBC hemolysis. Eur J Med Chem. 74:683–693.
2014. View Article : Google Scholar
|
|
28
|
Katkar P, Coletta A, Castelli S, Sabino
GL, Couto RA, Ferreira AM and Desideri A: Effect of oxindolimine
copper(II) and zinc(II) complexes on human topoisomerase I
activity. Metallomics. 6:117–125. 2014. View Article : Google Scholar
|
|
29
|
Wang P, Leung CH, Ma DL, Lu W and Che CM:
Organoplatinum(II) complexes with nucleobase motifs as inhibitors
of human topoisomerase II catalytic activity. Chem Asian J.
5:2271–2280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao F, Chao H and Ji LN: DNA binding,
photocleavage, and topoisomerase inhibition of functionalized
ruthenium(II)-polypyridine complexes. Chem Biodivers. 5:1962–1979.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kou JF, Qian C, Wang JQ, Chen X, Wang LL,
Chao H and Ji LN: Chiral ruthenium(II) anthraquinone complexes as
dual inhibitors of topoisomerases I and II. J Biol Inorg Chem.
17:81–96. 2012. View Article : Google Scholar
|
|
32
|
Lin RW, Yang CN, Ku S, Ho CJ, Huang SB,
Yang MC, Chang HW, Lin CM, Hwang J, Chen YL, et al: CFS-1686 causes
cell cycle arrest at intra-S phase by interference of interaction
of topoisomerase 1 with DNA. PLoS One. 9:e1138322014. View Article : Google Scholar : PubMed/NCBI
|
